US2007155795A1PendingUtilityA1

Muscarinic agonists

56
Assignee: ACADIA PHARM INCPriority: Apr 28, 2000Filed: Feb 16, 2007Published: Jul 5, 2007
Est. expiryApr 28, 2020(expired)· nominal 20-yr term from priority
A61P 43/00C07D 401/06C07D 413/06A61P 25/04A61P 25/14A61P 25/16C07D 409/06A61P 25/20A61P 27/02C07D 413/12A61P 25/24C07D 471/04C07D 487/04C07D 473/00A61P 25/18C07D 417/06C07D 405/06A61P 29/00A61P 25/02A61P 25/28A61P 27/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Claims

exact text as granted — not AI-modified
1 - 76 . (canceled)  
   
   
       77 . A compound of formula (I):  
     
       
         
         
             
             
         
       
       wherein:  
       Z 1  is CR 1 , Z 2  is CR 2 , Z 3  is CR 3 , and Z 4  is CR 4 ;  
       W 1  is S, W 2  is N or CR 6 , and W 3  is CG;  
       G is of formula (II):  
       
         
           
           
               
               
           
         
       
       Y is O, S, CHOH, —NHC(O)—, —C(O)NH—, —C(O)—, —OC(O)—, —(O)CO—, —NR 7 —, —CH═N—, or absent;  
       p is 1, 2, 3, 4 or 5;  
       Z is CR 8 R 9  or absent;  
       each t is 1, 2, or 3;  
       each R 1 , R 2 , R 3 , and R 4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  heteroalkyl, C 1-6  haloalkyl, —CN, —CF 3 , —OR 11 , —COR 11 , —NO 2 , —SR 11 , —NHC(O)R 11 , —C(O)NR 12 R 13 , —NR 12 R 13 , NR 11 C(O)NR 12 R 13 , —SO 2 NR 12 R 13 , —OC(O)R 11 , —O(CH 2 ) q NR 12 R 13 , or —(CH 2 ) q NR 12 R 13 , where q is an integer from 2 to 6, or R 1  and R 2  together form —NH—N═N— or R 3  and R 4  together form —NH—N═N—;  
       each R 5 , R 6 , and R 7 , independently, is H, C 1-6  alkyl; formyl; C 3-6  cycloalkyl; C 5-6  aryl, optionally substituted with halo or C 1-6  alkyl; or C 5-6  heteroaryl, optionally substituted with halo or C 1-6  alkyl;  
       each R 8  and R 9 , independently, is H or straight- or branched-chain C 1-8  alkyl;  
       R 10  is straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 1-8  alkylidene, C 1-8  alkoxy, or C 1-8  heteroalkyl;  
       R 10 ′ is H, straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 1-8  alkylidene, C 1-8  alkoxy, C 1-8  heteroalkyl, C 1-8  aminoalkyl, C 1-8  haloalkyl, C 1-8  alkoxycarbonyl, C 1-8  hydroxyalkoxy, C 1-8  hydroxyalkyl, or C 1-8  alkylthio;  
       each R 11 , independently, is H, straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 2-8  heteroalkyl, C 2-8  aminoalkyl, C 2-8  haloalkyl, C 1-8  alkoxycarbonyl, C 2-8  hydroxyalkyl, —C(O)—C 5-6  aryl substituted with C 1-3  alkyl or halo, C 5-6  aryl, C 5-6  heteroaryl, C 5-6  cycloalkyl, C 5-6  heterocycloalkyl, —C(O)NR 12 R 13 , —CR 5 R 12 R 13 , —(CH 2 ) t NR 12 R 13 , t is an integer from 2 to 8; and  
       each R 12  and R 13 , independently, is H, C 1-6  alkyl; C 3-6  cycloalkyl; C 5-6  aryl, optionally substituted with halo or C 1-6  alkyl; or C 5-6  heteroaryl, optionally substituted with halo or C 1-6  alkyl;  
       or a pharmaceutically acceptable salt, ester or prodrug thereof.  
     
   
   
       78 . The compound of  claim 77 , wherein each t is 2.  
   
   
       79 . The compound of  claim 78 , wherein R 10  is n-butyl.  
   
   
       80 . The compound of  claim 78 , wherein each R 1 , R 2 , R 3 , and R 4 , independently, is H, hydroxyl, halo, C 1-6  heteroalkyl, CF 3 , —NO 2 , or straight- or branched-chain C 1-6  alkyl, or R 1  and R 2  together form —NH—N═N— or R 3  and R 4  together form —NH—N═N—.  
   
   
       81 . The compound of  claim 78 , wherein Y is absent or O, p is 0, 1, 2 or 3, and R 8  and R 9  are H.  
   
   
       82 . The compound of  claim 81 , wherein Z is absent, Y is absent and p is 3.  
   
   
       83 . The compound of  claim 82 , wherein R 10  is n-butyl.  
   
   
       84 . The compound of  claim 77 , wherein the compound is: 
 1-benzo[b]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one;    4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo[b]thiophen-2-yl)-butan-1-one;    1-(3-bromo-benzo[b]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one    1-(3-benzo[b]thiophen-2-yl-propyl)-4-butylpiperidine;    4-butyl-1-[3-(5-fluoro-3-methyl-benzo[b]thiophen-2-yl)-propyl]-piperidine;    1-(3-benzo [b]thiophen-2-yl-propyl)-4-methylpiperidine    1-(3-benzo[b]thiophen-2-yl-propyl)-4-benzylpiperidine; or    3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[d]isothiazole.    
   
   
       85 . A pharmaceutical composition comprising an effective amount of a compound of formula (I):  
     
       
         
         
             
             
         
       
       wherein:  
       Z 1  is CR 1 , Z 2  is CR 2 ,Z 3  is CR 3 , and Z 4 is CR 4 ;  
       W 1  is S, W 2  is N or CR 6 , and W 3  is CG;  
       G is of formula (II):  
       
         
           
           
               
               
           
         
       
       Y is O, S, CHOH, —NHC(O)—, —C(O)NH—, —C(O)—, —OC(O)—, —(O)CO—, —NR 7 —, —CH═N—, or absent;  
       p is 1, 2, 3, 4 or 5;  
       Z is CR 8 R 9  or absent;  
       each t is 1, 2, or 3;  
       each R 1 , R 2 , R 3 , and R 4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  heteroalkyl, C 1-6  haloalkyl, —CN, —CF 3 , —OR 11 , —COR 11 , —NO 2 , —SR 11 , —NHC(O)R 11 , —C(O)NR 12 R 13 , —NR 12 R 13 , NR 11 C(O)NR 12 R 13 , —SO 2 NR 12 R 13 , —OC(O)R 11 , —O(CH 2 ) q NR 12 R 13 , or —(CH 2 ) q NR 12 R 13 , where q is an integer from 2 to 6, or R 1  and R 2  together form —NH—N═N— or R 3  and R 4  together form —NH—N═N—;  
       each R 5 , R 6 , and R 7 , independently, is H, C 1-6  alkyl; formyl; C 3-6  cycloalkyl; C 5-6  aryl, optionally substituted with halo or C 1-6  alkyl; or C 5-6  heteroaryl, optionally substituted with halo or C 1-6  alkyl;  
       each R 8  and R 9 , independently, is H or straight- or branched-chain C 1-8  alkyl;  
       R 10  is straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 1-8  alkylidene, C 1-8  alkoxy, or C 1-8  heteroalkyl;  
       R 10 ′ is H, straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 1-8  alkylidene, C 1-8  alkoxy, C 1-8  heteroalkyl, C 1-8  aminoalkyl, C 1-8  haloalkyl, C 1-8  alkoxycarbonyl, C 1-8  hydroxyalkoxy, C 1-8  hydroxyalkyl, or C 1-8  alkylthio;  
       each R 11 , independently, is H, straight- or branched-chain C 1-8  alkyl, C 2-8  alkenyl, C 2-8  alkynyl, C 2-8  heteroalkyl, C 2-8  aminoalkyl, C 2-8  haloalkyl, C 1-8  alkoxycarbonyl, C 2-8  hydroxyalkyl, —C(O)—C 5-6  aryl substituted with C 1-3  alkyl or halo, C 5-6  aryl, C 5-6  heteroaryl, C 5-6  cycloalkyl, C 5-6  heterocycloalkyl, —C(O)NR 12 R 13 , —CR 5 R 12 R 13 , —(CH 2 ) t NR 12 R 13 , t is an integer from 2 to 8; and  
       each R 12  and R 1-3 , independently, is H, C 1-6  alkyl; C 3-6  cycloalkyl; C 5-6  aryl, optionally substituted with halo or C 1-6  alkyl; or C 5-6  heteroaryl, optionally substituted with halo or C 1-6  alkyl;  
       or a pharmaceutically acceptable salt, ester or prodrug thereof.  
     
   
   
       86 . A pharmaceutical composition of  claim 85 , wherein each t is 2.  
   
   
       87 . A pharmaceutical composition of  claim 86 , wherein R 10  is n-butyl.  
   
   
       88 . A pharmaceutical composition of  claim 86 , wherein each R 1 , R 2 , R 3 , and R 4 , independently, is H, hydroxyl, halo, C 1-6 heteroalkyl, CF 3 , —NO 2 , or straight- or branched-chain C 1-6  alkyl, or R 1  and R 2  together form —NH—N═N— or R 3  and R 4  together form —NH—N═N—.  
   
   
       89 . A pharmaceutical composition of  claim 86 , wherein Y is absent or O, p is 0, 1, 2 or 3, and R 8  and R 9  are H.  
   
   
       90 . A pharmaceutical composition of  claim 89 , wherein Z is absent, Y is absent and p is 3.  
   
   
       91 . A pharmaceutical composition of  claim 90 , wherein R 10  is n-butyl.  
   
   
       92 . A pharmaceutical composition of  claim 86 , wherein the compound is: 
 1-benzo[b]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one;    4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo [b]thiophen-2-yl)-butan-1-one;    1-(3-bromo-benzo [b]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one    1-(3-benzo [b]thiophen-2-yl-propyl)-4-butylpiperidine;    4-butyl-1-[3-(5-fluoro-3-methyl-benzo [b]thiophen-2-yl)-propyl]-piperidine;    1-(3-benzo [b]thiophen-2-yl-propyl)-4-methylpiperidine;    1-(3-benzo[b]thiophen-2-yl-propyl)-4-benzylpiperidine; or    3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[d]isothiazole.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.